SUBA-Itraconazole: Phase IIb started

HedgePath began the open-label, U.S. Phase IIb SCORING trial to evaluate 100 mg oral SUBA-Itraconazole twice daily in up to 40 patients with nevoid basal cell carcinoma syndrome (Gorlin syndrome). Hed...